COMPANY PROFILE

OncoPep

Explore full profile

OncoPep develops a multi-peptide therapeutic vaccine to prevent the progression of cancer

Boston, United StatesFounded 2010Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About OncoPep

OncoPep is a biotechnology company focused on developing innovative cancer vaccines aimed at preventing the progression of various cancers, including multiple myeloma and triple-negative breast cancer (TNBC). The company operates in the biopharmaceutical market, primarily serving cancer patients and healthcare providers. OncoPep's business model revolves around the research, development, and clinical testing of its lead investigational vaccine, PVX 410, which is designed to stimulate the patient's immune system to combat cancer cells. The company generates revenue through partnerships, grants, and potential future sales of its vaccines upon regulatory approval. Currently, PVX 410 is in Phase 2 clinical trials for smoldering multiple myeloma (SMM) and is being evaluated for its efficacy both as a standalone treatment and in combination with other immunomodulatory agents.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: Boston, United States
Employees: 4
Open positions: None listed
Dealroom signal: 59.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES D✓Equity / VC	Dec 2021	$11M	$44M	SX Company · Kukje Pharma · OmniAb · Tera Science	↗
SERIES CEquity / VC	Jan 2020	$16M	$62M	Cobro Ventures	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

OncoPep website traffic

Latest recorded traffic for OncoPep is 620 monthly website visits, down 27.9% over the last three months. OncoPep's team grew 0% over the past year.

Latest monthly visits620 3-month web change-27.9% 1-year team growth0%

Monthly website visitsApr 2016–Dec 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EPEpiPawsOffering DNA testing for pets in order to estimate their age	Fort Lauderdale, United States	Operational	12	$25K	—
TPTME PharmaDeveloping novel therapies for treatment of the most aggressive cancers by acting on the tumor microenvironment (TME)	Berlin, Germany	Operational
ELElephasA live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development	Garrett Park, United States	Operational
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational
FEFecundisSperm-enhancing technologies increasing infertility treatment success	Rosario, Argentina	Operational
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
ATAtsena TherapeuticsBringing the life-changing power of genetic medicine to reverse or prevent blindness	Durham, United States	Operational
BBBimini BiotechBIMINI Biotech develops innovative therapeutic strategies for oncology	Leiden, Netherlands	Operational